Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
Early data observed from NAVAL-1 in R/R EBV+ PTCL consistent with Phase 1b/2 clinical trialSAN DIEGO, June 28, 2023 (GLOBE...